Actual bioavailability of divalproex sodium extended-release tablets and its clinical implications
AUTOR(ES)
Fagiolino, Pietro, Martín, Omar, González, Nicolás, Malanga, Antonio
FONTE
Journal of Epilepsy and Clinical Neurophysiology
DATA DE PUBLICAÇÃO
2007-06
RESUMO
Divalproex sodium extended-release dosage form (divalproex-ER) has been promoted as innovative formulation for the treatment of epilepsy and manic disorders, and for migraine headache prevention, with the advantage of being dosing once a day. Due to a significant decreasing in the peak-trough fluctuation of plasma valproic acid levels, in comparison with the twice-daily dosing of conventional delayed-release formulations (divalproex-DR), concentration-dependent side effects would be prevented. However the main constraint for divalproex-ER usage is the need to be administered in a higher daily dose, because of its lower bioavailability, in order to prevent eventual breakthrough seizures when patients are switched from the twice-daily divalproex DR regimen. Taking into account free plasma drug levels, divalproex ER/DR relative bioavailability could be assessed as low as 75% in fasting condition. In order to overcome the need of increase divalproex-ER daily dose, maintenance of the twice-daily regimen is suggested. Divalproex-ER administered every 12 hours not only increases steady state trough concentration to a higher value in comparison with divalproex-DR, avoiding inefficacy of the treatment, but also achieves the safest manner to treat patients with valproic acid because of reaching practically a plateau profile of drug levels.
Documentos Relacionados
- Preparation and scale up of extended-release tablets of bromopride
- Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin
- Comparison of dissolution profile of extended-release oral dosage forms - two one-sided equivalence test
- Pharmacokinetics and Behavioral Effects of an Extended-Release, Liposome-Encapsulated Preparation of Oxymorphone in Rhesus Macaques
- Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate